Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease

被引:0
|
作者
Wang, Yan [1 ,2 ]
Li, Fangyu [1 ,2 ]
Qin, Qi [1 ,2 ]
Li, Tingting [1 ,2 ]
Wang, Qi [1 ,2 ]
Li, Yan [1 ,2 ]
Li, Ying [1 ,2 ]
Jia, Jianping [1 ,2 ,3 ,4 ,5 ]
机构
[1] Capital Med Univ, Xuanwu Hosp, Innovat Ctr Neurol Disorders, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
[2] Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Neurol, Beijing, Peoples R China
[3] Capital Med Univ, Clin Ctr Neurodegenerat Dis & Memory Impairment, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Inst Brain Disorders, Ctr Alzheimers Dis, Collaborat Innovat Ctr Brain Disorders, Beijing, Peoples R China
[5] Minist Educ, Key Lab Neurodegenerat Dis, Beijing, Peoples R China
来源
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE | 2025年 / 12卷 / 04期
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
Alzheimer's disease; Apolipoprotein E; Mild cognitive impairment; Biomarker; Cognitive decline; CEREBROSPINAL-FLUID; TAU; METAANALYSIS; LOCI; BETA;
D O I
10.1016/j.tjpad.2025.100065
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Apolipoprotein E epsilon 4 (APOE epsilon 4) bring the higher risk of Alzheimer' Disease (AD). It is essential to evaluate whether the diagnostic performances and critical values of cerebrospinal fluid (CSF) biomarkers are influenced by APOE epsilon 4, which has guiding significance for the clinical practical application. Methods: The differences in CSF biomarkers and their performances between APOE epsilon 4 carriers and non-carriers in distinguishing AD, mild cognitive impairment (MCI) and preclinical AD from normal controls (NCs) were analyzed. The receiver operating characteristic (ROC) curves were generated to compare the area under the curve (AUC) between APOE epsilon 4 carriers and non-carriers, as well as the critical values corresponding Youden Index. Results: In a cross sectional convenience sample of 1610 participants, lower A beta 42 and A beta 42/A beta 40 and higher p-Tau 181/A beta 42 in CSF were observed among APOE epsilon 4 carriers than non-carriers in NC, MCI, and AD groups (P< 0.05). The performance of CSF p-tau/A beta 42 in distinguishing MCI from NC among APOE epsilon 4 carriers was superior to non-carriers [AUC: 0.714 (95%CI: 0.673- 0.752) vs 0.600 (95%CI: 0.564- 0.634), P< 0.001], although it was similar in distinguishing AD from NC between APOE epsilon 4 carriers and non-carriers [AUC: 0.874 (95%CI: 0.835-0.906) vs 0.876 (95%CI: 0.843- 0.904)]. In the longitudinal cohort of 254 participants, the association of CSF A beta 42, A beta 42/A beta 40 and p-Tau181/A beta 42 with cognitive decline were stronger in APOE epsilon 4 carriers compared to non-carriers (P< 0.05). Meanwhile, the critical values were different depending on APOE genotype. Discussion: The CSF level of p-Tau181/A beta 42 was significantly different between APOE epsilon 4 carriers and non-carriers at different stages of AD. The results indicate that the performances of CSF biomarkers are influenced by APOE epsilon 4, which should be considered in the practical application.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Clinical significance of plasma candidate biomarkers of Alzheimer's Disease
    Lewczuk, Piotr
    Lukaszewicz-Zajac, Marta
    Kornhuber, Johannes
    Mroczko, Barbara
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2024, 58 (04) : 363 - 379
  • [42] Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease
    Schmand, B.
    Huizenga, H. M.
    van Gool, W. A.
    PSYCHOLOGICAL MEDICINE, 2010, 40 (01) : 135 - 145
  • [43] Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer's Disease
    Monge-Garcia, Victoria
    Garcia-Ayllon, Maria-Salud
    Saez-Valero, Javier
    Sanchez-Paya, Jose
    Navarrete-Rueda, Francisco
    Manzanares-Robles, Jorge
    Gasparini-Berenguer, Ruth
    Romero-Lorenzo, Raquel
    Cortes-Gomez, Maria Angeles
    Monge-Argiles, Jose-Antonio
    MEDICINA-LITHUANIA, 2021, 57 (09):
  • [44] Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease
    Zetterberg, Henrik
    Lunn, Michael P.
    Herukka, Sanna-Kaisa
    BIOMARKERS IN MEDICINE, 2012, 6 (04) : 371 - 376
  • [45] CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment
    Blennow, K
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2005, 5 (05) : 661 - 672
  • [46] Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
    Hansson, Oskar
    Rutz, Sandra
    Zetterberg, Henrik
    Bauer, Ekaterina
    Haehl, Teresa
    Manuilova, Ekaterina
    Mert, Mehmet Can
    Wahl, Simone
    Blennow, Kaj
    Stomrud, Erik
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2020, 12 (01)
  • [47] Could Clinical Profile Influence CSF Biomarkers in Early-onset Alzheimer Disease?
    Koric, Lejla
    Felician, Olivier
    Guedj, Eric
    Hubert, Anne Michele
    Mancini, Julien
    Boucraut, Jose
    Ceccaldi, Mathieu
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2010, 24 (03) : 278 - 283
  • [48] Cerebrospinal fluid biomarkers of Alzheimer's disease
    Sui, Xiaojing
    Liu, Jianjun
    Yang, Xifei
    NEUROSCIENCE BULLETIN, 2014, 30 (02) : 233 - 242
  • [49] CSF biomarkers in patients with epilepsy in Alzheimer's disease: a nation-wide study
    Banote, Rakesh Kumar
    Hakansson, Samuel
    Zetterberg, Henrik
    Zelano, Johan
    BRAIN COMMUNICATIONS, 2022, 4 (04)
  • [50] Biomarkers of synaptic degeneration in Alzheimer's disease
    Cheng, Qian
    Fan, Yiou
    Zhang, Pengfei
    Liu, Huan
    Han, Jialin
    Yu, Qian
    Wang, Xueying
    Wu, Shuang
    Lu, Zhiming
    AGEING RESEARCH REVIEWS, 2025, 104